Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomustine SCHEMBL868328 | 1.00 | ADRA2A (1.00) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Lomustine SCHEMBL28262197 | 0.97 | ADRA2A (0.94) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Lomustine SCHEMBL28159683 | 0.95 | ADRA2A (0.91) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Lomustine SCHEMBL28123007 | 0.95 | ADRA2A (0.91) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Lomustine SCHEMBL1831239 | 0.93 | ADRA2A (0.86) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Semustine SCHEMBL2350016 | 0.91 | ALDH1A1 (0.92) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| Lomustine SCHEMBL863570 | 0.91 | ADRA2A (0.83) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| SCHEMBL4634654 | 0.88 | ADRA2A (0.79) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| SCHEMBL3341311 | 0.87 | ADRA2A (0.77) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 | |
| SCHEMBL3341308 | 0.87 | ADRA2A (0.77) | ADRA2APDE4AADRA1AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 136148 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137650-A1 | MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) | 11949098 CANADA INC (CA) | 2026-05-21 | — | — | US | claimed |
| US-20260139071-A1 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| WO-1989007453-A1 | MEDICINAL PREPARATIONS CHARACTERIZED BY A COMBINATION OF CYTOSTATIC AGENTS, HORMONAL THERAPEUTIC AGENTS AND PHOSPHONE DERIVATIVES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1989-08-24 | — | — | WO | claimed |
| WO-1989002734-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-04-06 | — | — | WO | claimed |
| EP-0273754-A2 | Method of enhancing the biodistribution of antibody for localization in lesions | CITY OF HOPE NATIONAL MEDICAL CENTER (US) | 1988-07-06 | — | — | EP | claimed |
| EP-0227593-A1 | Use of chelating agents | THE HOSPITAL FOR SICK CHILDREN (CA) | 1987-07-01 | — | — | EP | claimed |
| US-4631289-A | ANTITUMOR AGENTS; CELL SENSITIZATION | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-12-23 | — | — | US | claimed |
| EP-0095906-B1 | IMPROVEMENTS RELATING TO COMPOUNDS USEFUL IN RADIOTHERAPY OR CHEMOTHERAPY | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-10-22 | — | — | EP | claimed |
| EP-0189849-A2 | Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans | Sloan-Kettering Institute For Cancer Research (US) | 1986-08-06 | — | — | EP | claimed |
| EP-0120907-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | Aston Molecules Limited (GB) | 1984-10-10 | — | — | EP | claimed |
| WO-1984001506-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | UNIV BIRMINGHAM (GB) | 1984-04-26 | — | — | WO | claimed |
| EP-0095906-A1 | Improvements relating to compounds useful in radiotherapy or chemotherapy | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-12-07 | — | — | EP | claimed |